

# **Review of Metabolic and Bioengineering Strategies for $\alpha$ -Ketoisovalerate ( $\alpha$ -KIV) Production in *Escherichia coli***

---

*With Emphasis on Lactate as a Carbon Source*

Literature Review  
February 2026

*Compiled with searches across PubMed, bioRxiv, and the wider literature*

# 1. Biosynthetic Pathway Engineering

## 1.1 The Core Pathway: Pyruvate to $\alpha$ -KIV

$\alpha$ -Ketoisovalerate (2-ketoisovalerate,  $\alpha$ -KIV) is a branched-chain  $\alpha$ -keto acid that sits at the junction of valine, leucine, and pantothenate biosynthesis in *E. coli*. It is synthesised from pyruvate via three enzymatic steps in the branched-chain amino acid (BCAA) pathway:

**Step 1 - Acetolactate synthase (ALS/AHAS):** Two molecules of pyruvate are condensed to form 2-acetolactate with the loss of  $\text{CO}_2$ . *E. coli* encodes three AHAS isoenzymes: AHAS I (*ilvBN*), AHAS II (*ilvGM*, inactive in K-12 strains due to a frameshift mutation), and AHAS III (*ilvIH*). For production purposes, *Bacillus subtilis* AlsS is the preferred heterologous enzyme, as it exhibits higher catalytic activity and reduced sensitivity to feedback inhibition (Atsumi et al., 2008, *Nature* 451:86-89; DOI: 10.1038/nature06450).

**Step 2 - Ketol-acid reductoisomerase (KARI, *IlvC*):** 2-Acetolactate is reduced and isomerised to 2,3-dihydroxyisovalerate. This NADPH-dependent step is a major cofactor bottleneck (discussed in Section 1.3).

**Step 3 - Dihydroxyacid dehydratase (DHAD, *IlvD*):** 2,3-Dihydroxyisovalerate is dehydrated to yield  $\alpha$ -KIV. This [4Fe-4S] cluster enzyme is oxygen-sensitive, which has implications for aerobic bioprocesses.

## 1.2 Highest Reported Titres

The current benchmark for  $\alpha$ -KIV production was set by Zhou et al. (2022, *Applied and Environmental Microbiology* 88:e0097622; DOI: 10.1128/aem.00976-22). Using strain 050TY/pCTSDTQ487S-RBS55, they achieved **55.8 g/L  $\alpha$ -KIV** with a productivity of **2.14 g/L/h** and a yield of **0.852 mol/mol glucose** (approximately 84% of the theoretical maximum) in a two-phase fed-batch fermentation. Key engineering strategies included:

Deletion of competing routes (*leuA*, *ilvE*, *panB*) to prevent  $\alpha$ -KIV consumption by leucine, valine, and pantothenate biosynthesis.

Overexpression of AlsS, *IlvC*, and *IlvD* with systematic optimisation of gene order on the plasmid and inclusion of terminators to balance expression levels.

Tuning NADPH supply through chromosomal pyridine nucleotide transhydrogenase (*sthA/udhA*) expression.

Enhancing aerobic respiration to recycle excess NADH accumulated during  $\alpha$ -KIV biosynthesis.

Fusing a protein degradation tag to pyruvate dehydrogenase (PDH) E1 subunit. Under the aerobic growth phase, PDH is active; upon switching to microaerobic conditions, PDH is degraded, curtailing pyruvate flux into the TCA cycle and channelling it toward  $\alpha$ -KIV.

Modification of acetolactate synthase to reduce the promiscuous decarboxylation side-reaction producing isobutyraldehyde.

For context, the foundational work by Atsumi, Hanai & Liao (2008, *Nature* 451:86-89; DOI: 10.1038/nature06450) demonstrated >20 g/L isobutanol (which transits through  $\alpha$ -KIV as an intermediate) in 112 h using strain JCL260 with six gene deletions (*adhE*, *frdBC*, *fnr*, *ldhA*,

*pta*, *pflB*) and overexpression of *B. subtilis* AlsS, *E. coli* IlvC/IlvD, *L. lactis* Kivd, and *S. cerevisiae* ADH2.

More recently, Carranza-Saavedra et al. (2023, *Frontiers in Bioengineering and Biotechnology* 11:1176445; DOI: 10.3389/fbioe.2023.1176445) validated *E. coli* W as a chassis for  $\alpha$ -KIV production from unconventional feedstocks. Using whey lactose, strain W1262 produced **3.22 g/L  $\alpha$ -KIV + 1.40 g/L valine** (4.62 g/L total products from 3.9 g/L whey lactose), demonstrating yields exceeding 100% on a carbon basis due to supplementary nutrients in the whey matrix.

### 1.3 Cofactor Engineering: The KARI Bottleneck

The redox imbalance inherent to  $\alpha$ -KIV biosynthesis from glucose is a central engineering challenge. For each mole of  $\alpha$ -KIV produced, two moles of NADH are generated (via glycolysis) but one mole of NADPH is consumed (by KARI). Under fermentative or microaerobic conditions, NADH accumulates while NADPH supply is limiting, creating a stoichiometric mismatch.

Bastian et al. (2011, *Metabolic Engineering* 13:345-352) engineered both KARI and ADH to use NADH instead of NADPH, enabling anaerobic isobutanol production approaching theoretical yield. This represented a proof-of-concept that cofactor switching could resolve the redox bottleneck.

The definitive cofactor-switching work was reported by Brinkmann-Chen et al. (2013, *PNAS* 110:10946-10951; DOI: 10.1073/pnas.1306073110), who developed a **general recipe for reversing KARI cofactor specificity from NADPH to NADH**. The *E. coli* IlvC variant Ec\_Ilvc6E6, carrying four mutations (Ala71Ser, Arg76Asp, Ser78Asp, Gln110Val) in the  $\beta$ 2 $\alpha$ B-loop of the Rossmann fold, achieved a **54,000-fold reversal in cofactor specificity** while retaining 85% of wild-type catalytic activity with NADH. Crystal structures revealed that these mutations disrupt contacts with the 2'-phosphate group of NADPH. Critically, the same mutation strategy was successfully applied to five different KARIs from diverse organisms, confirming its generality.

A follow-up study (Brinkmann-Chen et al., 2014) identified naturally NADH-preferring KARIs from nature with catalytic efficiencies exceeding even the engineered variants, expanding the toolkit further.

### 1.4 Feedback Inhibition and Its Relief

In wild-type *E. coli*, the BCAA pathway is subject to tight feedback regulation at multiple levels. AHAS I (*ilvBN*) and AHAS III (*ilvIH*) are inhibited by valine, while the *ilvGMEDA* operon is regulated by transcriptional attenuation in response to all three BCAAs. Park et al. (2007, *PNAS*; DOI: 10.1073/pnas.0702609104) addressed both levels simultaneously for valine overproduction: they removed feedback inhibition of AHAS III through site-directed mutagenesis and replaced native promoters (which contain attenuator regions) with the *tac* promoter, achieving deregulated expression.

Work in *Corynebacterium glutamicum* by Radykova et al. (2005, *Journal of Bacteriology* 187:1357-1365; DOI: 10.1128/jb.187.4.1357-1365.2005) identified the M13 mutation in IlvN (the regulatory subunit of AHAS) that confers feedback resistance to all three BCAAs, providing transferable insights for *E. coli* engineering.

Yamamoto et al. (2017, *Advances in Biochemical Engineering/Biotechnology* 159:103-128; DOI: 10.1007/10\_2016\_28) provide a comprehensive review of BCAA biosynthesis regulation and engineering strategies across multiple hosts.

## 2. Competing Pathway Knockouts and Flux Redirection

### 2.1 Standard Deletions for $\alpha$ -KIV Accumulation

Since  $\alpha$ -KIV is a branchpoint metabolite, preventing its consumption is essential. The standard deletion set, consistently employed across the literature, comprises:

**$\Delta$ leuA** (2-isopropylmalate synthase): prevents the first committed step of leucine biosynthesis from  $\alpha$ -KIV.

**$\Delta$ ilvE** (branched-chain amino acid aminotransferase): prevents transamination of  $\alpha$ -KIV to valine.

**$\Delta$ panB** (3-methyl-2-oxobutanoate hydroxymethyltransferase/KPHMT): prevents diversion to pantothenate biosynthesis.

These three deletions render the host auxotrophic for valine, leucine, and pantothenate, requiring supplementation in the growth medium.

### 2.2 Fermentation Byproduct Elimination

To maximise carbon flux from pyruvate to  $\alpha$ -KIV, deletions targeting fermentative byproduct pathways are standard practice: *adhE* (ethanol), *ldhA* (lactate), *pflB* (formate), *pta* (acetate via phosphotransacetylase), *frdBC* (succinate), and *poxB* (acetate via pyruvate oxidase). The six-deletion strain JCL260 from Atsumi et al. (2008) represents the canonical background.

### 2.3 PDH as a Conditional Target

Pyruvate dehydrogenase (PDH) represents a major competing drain on pyruvate, but its complete deletion is lethal under standard aerobic growth conditions. Zhou et al. (2022) elegantly addressed this with a degradation tag strategy: PDH is active during aerobic biomass accumulation but is proteolytically degraded upon transition to microaerobic production conditions, effectively decoupling growth from production.

### 2.4 Unexpected Side Reactions

Deb et al. (2019, *Biotechnology Letters* 41:823-836; DOI: 10.1007/s10529-019-02683-5) highlighted an important cautionary finding. When constructing isobutanol-producing strains with chromosomally integrated pathway genes (avoiding plasmid instability), they discovered significant accumulation of 2,3-butanediol and acetol from isobutyraldehyde, indicating activation of alternative metabolic pathways not previously considered. This underscores the importance of accounting for promiscuous enzyme activities when designing production strains.

### 2.5 Adaptive Laboratory Evolution

Atsumi et al. (2010, *Molecular Systems Biology* 6:449; DOI: 10.1038/msb.2010.98) conducted ALE campaigns to improve isobutanol tolerance in *E. coli*. Genomic analysis of tolerant strain SA481 revealed mutations affecting membrane composition and stress

responses. While not directly targeting  $\alpha$ -KIV accumulation, improved solvent tolerance is relevant to high-titre production where product toxicity limits performance.

### 3. Lactate as a Carbon Source

#### 3.1 Native Lactate Assimilation in *E. coli*

*E. coli* possesses native machinery for aerobic lactate utilisation. The *lldPRD* operon encodes L-lactate permease (LldP), a membrane-bound FMN-dependent L-lactate dehydrogenase (LldD) that oxidises L-lactate to pyruvate, and a transcriptional regulator (LldR). For D-lactate, the membrane-bound D-lactate dehydrogenase (Dld) performs the analogous oxidation. Both enzymes feed electrons into the respiratory chain rather than generating soluble NADH, making lactate oxidation obligately aerobic.

#### 3.2 Metabolic Flux Considerations

When lactate serves as the sole carbon source, all carbon enters central metabolism as pyruvate, placing it immediately upstream of the  $\alpha$ -KIV pathway. This is conceptually advantageous: unlike glucose, there is no glycolytic network to compete for carbon, and the pyruvate pool should be directly available for BCAA pathway enzymes.

However, critical redox differences emerge. Glucose catabolism generates 2 NADH per pyruvate (via glycolysis), creating the redox surplus that Zhou et al. (2022) worked to manage. Lactate oxidation via LldD or Dld does *not* generate soluble NADH; instead, electrons enter the quinone pool directly. This means that when using lactate as feedstock, NADPH regeneration for KARI becomes even more challenging, as neither glycolytic NADH nor the pentose phosphate pathway are directly available. The use of NADH-dependent KARI variants (Brinkmann-Chen et al., 2013) would still be valuable, but a transhydrogenase or dedicated NADH-generation step would be needed.

#### 3.3 Adaptive Evolution for Enhanced Lactate Uptake

Hua et al. (2007, *Applied Microbiology and Biotechnology*) subjected *E. coli* to adaptive evolution on lactate as sole carbon source and observed up to 80% increases in lactate uptake rate within approximately 100 generations (20 days). Transcriptomic analysis revealed 14-fold upregulation of *dld* and enhanced *lldP* and *lldD* transcription, alongside downregulation of PTS sugar transporters. This demonstrates that *E. coli* can be rapidly adapted to efficient lactate utilisation.

#### 3.4 Preventing Lactate Re-consumption in Production Strains

Mazumdar et al. (2013) demonstrated the importance of *lldD* deletion when engineering *E. coli* for L-lactate *production* from glycerol, achieving 0.875 g/g yield (90% theoretical). While this work targeted lactate as a product rather than a substrate, the finding that *lldD* deletion was essential to prevent product consumption provides a key design principle: for lactate-to- $\alpha$ -KIV conversion, lactate oxidation must be carefully controlled to avoid futile cycling.

#### 3.5 Published Examples of BCAA/Keto-acid Production from Alternative Feedstocks

**No published studies report  $\alpha$ -KIV or isobutanol production from lactate as sole carbon source in *E. coli*.** This represents a clear gap in the literature. The closest

precedent is the work by Carranza-Saavedra et al. (2023) using whey lactose (a disaccharide, not lactate) in *E. coli* W, which demonstrated the feasibility of alternative carbon source utilisation for  $\alpha$ -KIV production.

The metabolic pathway from lactate to  $\alpha$ -KIV is thermodynamically feasible and metabolically straightforward: lactate  $\rightarrow$  pyruvate (via LldD/Dld)  $\rightarrow$  2-acetolactate (AlsS)  $\rightarrow$  2,3-dihydroxyisovalerate (IlvC)  $\rightarrow$   $\alpha$ -KIV (IlvD). The theoretical carbon yield from lactate to  $\alpha$ -KIV would need to account for the CO<sub>2</sub> loss at the AlsS step (2 pyruvate  $\rightarrow$  1 acetolactate + CO<sub>2</sub>), giving a maximum of 0.5 mol  $\alpha$ -KIV per mol lactate, or approximately 0.645 g/g.



## 4. Bioprocess and Fermentation Strategies

### 4.1 Two-Phase Fermentation

The most successful strategy reported is the two-phase approach of Zhou et al. (2022): aerobic growth followed by microaerobic production. This decouples biomass generation (requiring an active TCA cycle and oxidative phosphorylation) from product formation (requiring PDH suppression and pyruvate channelling to  $\alpha$ -KIV). The transition from aerobic to microaerobic conditions also triggers the degradation-tag-mediated removal of PDH, providing an elegant temporal switch.

### 4.2 Fed-Batch with In Situ Product Removal

For isobutanol production (downstream of  $\alpha$ -KIV), Baez et al. (2011, *Applied Microbiology and Biotechnology* 90:1681-1690; DOI: 10.1007/s00253-011-3173-y) demonstrated fed-batch fermentation with gas stripping for in situ product removal, overcoming the toxicity ceiling. While  $\alpha$ -KIV itself is less toxic than isobutanol, product inhibition at high concentrations (>50 g/L) may still be relevant.

### 4.3 Summary of Best Reported TRY Metrics

Strain	Product	Titre	Rate	Yield	Carbon Source	Reference
050TY/ pCTSDTQ487S- RBS55	$\alpha$ -KIV	<b>55.8 g/L</b>	2.14 g/L/h	0.852 mol/mol	Glucose	Zhou et al. 2022
<i>E. coli</i> W1262	$\alpha$ -KIV + Val	3.22 + 1.40 g/L	-	>100%*	Whey lactose	Carranza-Saavedra et al. 2023
JCL260/ pSA55/pSA69	Isobutanol	>20 g/L	-	-	Glucose	Atsumi et al. 2008
NADH-KARI strain	Isobutanol	Theoretical	-	~100%	Glucose	Bastian et al. 2011

\*Yield exceeds 100% on a carbon basis due to supplementary nutrients in whey.

### 4.4 Product Toxicity

$\alpha$ -KIV toxicity to *E. coli* is not well characterised in the literature. At the high titres reported by Zhou et al. (55.8 g/L), osmotic stress and metabolic perturbation are likely contributing factors to productivity decline, but specific toxicity mechanisms have not been dissected. Isobutanol toxicity (which limits its own production) has been studied more extensively, with membrane damage identified as the primary mechanism (Atsumi et al., 2010). This is less relevant for  $\alpha$ -KIV, which as a charged organic acid is unlikely to partition into membranes in the same way.

## 5. Emerging Tools and Approaches

### 5.1 Dynamic Regulation

The conditional PDH degradation strategy of Zhou et al. (2022) represents the most sophisticated example of dynamic regulation applied to  $\alpha$ -KIV production. More broadly, temperature-sensitive promoters (e.g. pR-pL from phage  $\lambda$ ) and quorum-sensing-based switches have been used in related pathways to separate growth and production phases. No  $\alpha$ -KIV-responsive biosensor has been reported to date, representing a significant gap.

### 5.2 Computational Approaches

Carranza-Saavedra et al. (2023) employed Monte Carlo sampling for flux variability analysis to guide strain design in *E. coli* W. Park et al. (2007) used transcriptome analysis to identify unexpected bottlenecks in valine production. Ensemble modelling approaches (Tran et al., 2008; Rizk & Liao, 2009) from the Liao group have been applied to related metabolic engineering problems and could be productively applied to  $\alpha$ -KIV pathway optimisation.

### 5.3 Cell-Free Systems

Grimaldi et al. (2016, *Biotechnology Progress* 32:66-73; DOI: 10.1002/btpr.2197) demonstrated cell-free isobutanol production using immobilised enzymes. While titres were low, this provides proof-of-concept that the  $\alpha$ -KIV pathway can function outside a cellular context, potentially relevant for whole-cell biocatalysis with lysate supplementation or cell-free biosensing applications.

### 5.4 Biosensors

No  $\alpha$ -KIV-specific biosensor has been reported. Potential development routes include transcription factor-based sensors using the native BCAA regulatory machinery (e.g. Lrp, the leucine-responsive regulatory protein), riboswitch engineering, or FRET-based approaches. An  $\alpha$ -KIV biosensor would enable high-throughput screening of pathway variants and dynamic pathway control, and represents an important enabling technology gap.

## 6. Gap Analysis and Future Directions

### 6.1 Critical Gaps

**No published work on lactate-to- $\alpha$ -KIV conversion in *E. coli*.** Despite clear metabolic feasibility (lactate  $\rightarrow$  pyruvate  $\rightarrow$   $\alpha$ -KIV), this carbon source has not been tested for  $\alpha$ -KIV or isobutanol production. This is the most striking gap relevant to a waste-to-chemicals pipeline.

**Limited alternative feedstock work.** Beyond whey lactose (Carranza-Saavedra et al., 2023), there is almost no literature on  $\alpha$ -KIV production from non-glucose feedstocks. Glycerol, lignocellulosic hydrolysates, and organic acid waste streams remain unexplored.

**No  $\alpha$ -KIV biosensor.** Real-time monitoring and dynamic control of  $\alpha$ -KIV accumulation cannot currently be achieved. This limits both fundamental understanding of pathway dynamics and applied screening throughput.

**Poorly characterised  $\alpha$ -KIV toxicity.** The mechanisms by which high  $\alpha$ -KIV concentrations limit cell growth and production have not been systematically studied.

**No continuous or perfusion processes.** All reported high-titre work uses batch or fed-batch fermentation. Continuous production could improve space-time yields and reduce downtime.

### 6.2 Feasibility Assessment: Lactate-to- $\alpha$ -KIV

Based on the available evidence, a lactate-to- $\alpha$ -KIV pipeline in *E. coli* is metabolically feasible with the following considerations:

**Carbon pathway:** Straightforward. Lactate  $\rightarrow$  pyruvate (native LldD/Dld)  $\rightarrow$   $\alpha$ -KIV (overexpressed AlsS/IlvC/IlvD). No novel enzymatic steps required.

**Redox balance:** More challenging than glucose. Lactate oxidation does not generate soluble NAD(P)H, so NADPH for KARI must come from alternative sources. Options include: (a) NADH-dependent KARI variants (Brinkmann-Chen et al., 2013), (b) membrane-bound transhydrogenase (PntAB) to convert NADH to NADPH, (c) heterologous NAD<sup>+</sup>-dependent lactate dehydrogenase to generate soluble NADH from lactate. Option (a) combined with (c) may be most effective.

**Uptake rate:** Native lactate uptake in *E. coli* may be limiting. Overexpression of LldP, heterologous transporter expression, or ALE (Hua et al., 2007) would likely be needed.

**Aerobic requirement:** Native lactate oxidation is obligately aerobic, while the highest  $\alpha$ -KIV titres were achieved under microaerobic conditions. This creates a tension that would need careful bioprocess design to resolve, potentially through two-phase operation or co-feeding strategies.

**Theoretical yield:** Maximum  $\sim 0.645$  g  $\alpha$ -KIV per g lactate (0.5 mol/mol), accounting for CO<sub>2</sub> loss at the AlsS step. This is lower than from glucose (0.852 mol/mol demonstrated) but could still be economically attractive if using waste lactate streams.

### 6.3 Recommended Next Experiments

- 1. Proof-of-concept strain:** Engineer *E. coli* with overexpressed *lldP* + BCAA pathway (AlsS, IlvC, IlvD) + standard deletions ( $\Delta leuA$ ,  $\Delta ilvE$ ,  $\Delta panB$ ) and test  $\alpha$ -KIV production from lactate in shake flasks.
- 2. Cofactor variant comparison:** Compare wild-type IlvC (NADPH-dependent) versus Ec\_Ilvc6E6 (NADH-dependent) with lactate feedstock to quantify the cofactor bottleneck severity.
- 3. Aerobic vs. microaerobic:** Systematically compare aerobic and microaerobic conditions for lactate-to- $\alpha$ -KIV conversion, as the oxygen requirement for lactate assimilation may conflict with the microaerobic optimum for  $\alpha$ -KIV accumulation.
- 4. Mixed feeding:** Evaluate glucose/lactate co-feeding, where glucose supports growth and cofactor regeneration while lactate provides additional pyruvate for  $\alpha$ -KIV production.
- 5. Biosensor development:** Develop a transcription-factor-based  $\alpha$ -KIV biosensor to enable high-throughput screening of pathway variants and dynamic control.
- 6. Scale-up considerations:** For waste lactate streams (e.g. from polylactic acid recycling or dairy waste), assess feedstock composition effects, sterilisation requirements, and any inhibitory contaminants.

## Key References

- Atsumi, S., Hanai, T. & Liao, J.C. (2008) Non-fermentative pathways for synthesis of branched-chain higher alcohols as biofuels. *Nature* 451:86-89. DOI: 10.1038/nature06450
- Atsumi, S. et al. (2010) Evolution, genomic analysis, and reconstruction of isobutanol tolerance in *Escherichia coli*. *Molecular Systems Biology* 6:449. DOI: 10.1038/msb.2010.98
- Baez, A., Cho, K.M. & Liao, J.C. (2011) High-flux isobutanol production using engineered *Escherichia coli*: a bioreactor study with in situ product removal. *Applied Microbiology and Biotechnology* 90:1681-1690. DOI: 10.1007/s00253-011-3173-y
- Bastian, S. et al. (2011) Engineered ketol-acid reductoisomerase and alcohol dehydrogenase enable anaerobic 2-methylpropan-1-ol production at theoretical yield in *Escherichia coli*. *Metabolic Engineering* 13:345-352.
- Brinkmann-Chen, S. et al. (2013) General approach to reversing ketol-acid reductoisomerase cofactor dependence from NADPH to NADH. *PNAS* 110:10946-10951. DOI: 10.1073/pnas.1306073110
- Carranza-Saavedra, D. et al. (2023) System metabolic engineering of *Escherichia coli* W for the production of 2-ketoisovalerate using unconventional feedstock. *Frontiers in Bioengineering and Biotechnology* 11:1176445. DOI: 10.3389/fbioe.2023.1176445
- Chen, X. et al. (2015) Production of C4 and C5 branched-chain alcohols by engineered *Escherichia coli*. *Journal of Industrial Microbiology & Biotechnology* 42:1473-1479. DOI: 10.1007/s10295-015-1656-z
- Deb, S.S., Reshamwala, S.M.S. & Lali, A.M. (2019) Activation of alternative metabolic pathways diverts carbon flux away from isobutanol formation in an engineered *Escherichia coli* strain. *Biotechnology Letters* 41:823-836. DOI: 10.1007/s10529-019-02683-5
- Grimaldi, J., Collins, C.H. & Belfort, G. (2016) Towards cell-free isobutanol production: development of a novel immobilized enzyme system. *Biotechnology Progress* 32:66-73. DOI: 10.1002/btpr.2197
- Park, J.H. et al. (2007) Metabolic engineering of *Escherichia coli* for the production of L-valine based on transcriptome analysis and in silico gene knockout simulation. *PNAS*. DOI: 10.1073/pnas.0702609104
- Radykova, E. et al. (2005) Feedback-resistant acetohydroxy acid synthase III from *Corynebacterium glutamicum*. *Journal of Bacteriology* 187:1357-1365. DOI: 10.1128/jb.187.4.1357-1365.2005
- Yamamoto, K., Tsuchisaka, A. & Yukawa, H. (2017) Branched-chain amino acids. *Advances in Biochemical Engineering/Biotechnology* 159:103-128. DOI: 10.1007/10\_2016\_28
- Zhou, L. et al. (2022) Evaluation of metabolic engineering strategies on 2-ketoisovalerate production by *Escherichia coli*. *Applied and Environmental Microbiology* 88:e0097622. DOI: 10.1128/aem.00976-22